Koers Cerulean Pharma Inc Nasdaq
Aandelen
US15708Q1058
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 2,62 mln. 2,42 mln. | Omzet 2025 * | 27,84 mln. 25,67 mln. | Marktkapitalisatie | 43,85 mln. 40,43 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -23 mln. -21,21 mln. | Nettowinst (verlies) 2025 * | -10 mln. -9,22 mln. | EV/omzet 2024 * | 16,7 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 1,58 x |
K/w-verhouding 2024 * |
-1,72
x | K/w-verhouding 2025 * |
-3,6
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,36% |
Recentste transcriptie over Cerulean Pharma Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Sabrina Johnson
FOU | Founder | 57 | 01-01-15 |
Annie Thurman
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-22 |
Jessica Hatheway
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robin Steele
BRD | Director/Board Member | 68 | 01-01-15 |
Cheryl Blanchard
BRD | Director/Board Member | 59 | 20-11-19 |
Chairman | 75 | 01-01-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+54,05% | 58,71 mld. | |
-2,02% | 41,31 mld. | |
+40,01% | 39,2 mld. | |
-10,22% | 27,4 mld. | |
+13,42% | 26,55 mld. | |
-21,60% | 18,98 mld. | |
+2,89% | 12,51 mld. | |
+22,40% | 11,94 mld. | |
+27,49% | 12,08 mld. |